# Clinical Studies for the Treatment of Advanced Solid Tumors

Source: https://onco.cc/trials/nct06825494/  
OnCo record `nct06825494` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Capecitabine, Oxaliplatin, Penpulimab and Tislelizumab in advanced solid tumours, run by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd., now recruiting.

## Summary

Clinical Studies for the Treatment of Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06825494 by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd., with 194 participants planned, started 2025-04-08 and due to reach its primary completion in 2026-03. Interventions recorded: LM-108 injection+Penpulimab+ Oxaliplatin+Capecitabine, Tislelizumab+Oxaliplatin+Capecitabine, LM-108 injection 10mg/kg +penpulimab, LM-108 injection 600mg + penpulimab and enpulimab+ Oxaliplatin+Capecitabine.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06825494
- Phase: 1/2
- Setting: An Open-label Phase Ib/II Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of LM-108 ± Penpulimab + Chemotherapy in Patients With Advanced Solid Tumors - Cohort A
- Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
- Enrolled: 194

## Sources

- ClinicalTrials.gov NCT06825494: https://clinicaltrials.gov/study/NCT06825494

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Capecitabine](https://onco.cc/drugs/capecitabine/), [Oxaliplatin](https://onco.cc/drugs/oxaliplatin/), [Penpulimab](https://onco.cc/drugs/penpulimab/), [Tislelizumab](https://onco.cc/drugs/tislelizumab/)
- companies: [Sino Biopharmaceutical (Chia Tai Tianqing)](https://onco.cc/companies/sino-biopharm/)

---
JSON: https://onco.cc/api/v1/entities/nct06825494.json